

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently amended) A therapeutic ~~agent~~ composition for treating glaucoma comprising a combination of pharmaceutically effective amounts of drugs consisting essentially of (i) a Rho kinase inhibitor or a salt or an ester thereof and (ii) a prostaglandin or a salt or ester thereof, and optionally a pharmaceutically acceptable carrier.

Claim 2. (currently amended) A therapeutic ~~agent~~ composition for treating glaucoma which comprises a combination of pharmaceutically effective amounts of drugs consisting essentially of (i) a Rho kinase inhibitor or a salt or an ester thereof and a (ii) prostaglandin or a salt or an ester thereof, wherein the actions of the Rho kinase inhibitor and the prostaglandin are complemented and/or

enhanced by each other, and optionally a pharmaceutically acceptable carrier.

Claim 3. (currently amended) The therapeutic ~~agent~~ composition for treating glaucoma as claimed in claim 1, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexane carboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine, or a salt or an ester thereof.

Claim 4. (currently amended) The therapeutic ~~agent~~ composition for treating glaucoma as claimed in claim 1, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

Claim 5. (withdrawn - currently amended) A method of treating glaucoma comprising administering to a patient pharmaceutically effective amounts of (i) a Rho kinase inhibitor or a salt or an ester thereof in a combination with (ii) a prostaglandin to a patient, or a salt or an ester thereof.

Claim 6. (withdrawn - currently amended) A method of treating glaucoma comprising administering to a patient pharmaceutically effective amounts of (i) a Rho kinase inhibitor or a salt or an ester thereof in a combination with (ii) a prostaglandin to a patient or a salt or an ester thereof, wherein the actions of the Rho kinase inhibitor or a salt or an ester thereof and the prostaglandin or a salt or an ester thereof are complemented and/or enhanced by each other.

Claim 7. (withdrawn - currently amended) The method of treating glaucoma as claimed in claim 5, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide, (R)-(+) -N-(1H-

pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine, or a salt or an ester thereof.

Claim 8. (withdrawn - currently amended) The method of treating glaucoma as claimed in claim 5, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

Claim 9. (cancelled)

Claim 10. (cancelled)

Claim 11. (cancelled)

Claim 12. (cancelled)

Claim 13. (currently amended) The therapeutic ~~agent~~ composition for treating glaucoma as claimed in claim 2, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide, (R)-(+) -N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-

(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine, or a salt or an ester thereof.

Claim 14. (currently amended) The therapeutic ~~agent~~ composition for treating glaucoma as claimed in claim 2, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

Claim 15. (currently amended) The therapeutic ~~agent~~ composition for treating glaucoma as claimed in claim 3, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

Claim 16. (currently amended) The therapeutic ~~agent~~ composition for treating glaucoma as claimed in claim 13, wherein the prostaglandin is isopropyl unoprostone,

latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

Claim 17. (withdrawn - currently amended) The method of treating glaucoma as claimed in claim 6, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl) cyclohexanecarboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine, or a salt or an ester thereof.

Claim 18. (withdrawn - currently amended) The method of treating glaucoma as claimed in claim 6, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

Claim 19. (withdrawn - currently amended) The method of treating glaucoma as claimed in claim 7, wherein the

prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

Claim 20. (withdrawn - currently amended) The method of treating glaucoma as claimed in claim 17, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

Claim 21. (new) The therapeutic composition for treating glaucoma as claimed in claim 1, wherein the combination of drugs is selected from the group consisting of

- (i) (R) - (+) -N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide dihydrochloride and isopropyl unoprostone;
- (ii) (R) - (+) -N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide dihydrochloride and latanoprost;
- (iii) 1-(5-isoquinolinesulfonyl)-homopiperazine dihydrochloride and isopropyl unoprostone; and
- (iv) 1-(5-isoquinolinesulfonyl)-homopiperazine dihydrochloride and latanoprost.

Claim 22. (new) The method of treating glaucoma as claimed in claim 5, wherein the combination is selected from the group consisting of

- (i) (R) - (+) -N - (1H-pyrrolo[2,3-b]pyridin-4-yl) -4 - (1-aminoethyl)benzamide dihydrochloride and isopropyl unoprostone;
- (ii) (R) - (+) -N - (1H-pyrrolo[2,3-b]pyridin-4-yl) -4 - (1-aminoethyl)benzamide dihydrochloride and latanoprost;
- (iii) 1-(5-isoquinolinesulfonyl)-homopiperazine dihydrochloride and isopropyl unoprostone; and
- (iv) 1-(5-isoquinolinesulfonyl)-homopiperazine dihydrochloride and latanoprost.